<DOC>
	<DOCNO>NCT00239564</DOCNO>
	<brief_summary>The objective compare pharmacokinetics pharmacodynamics IPX054 carbidopa-levodopa immediate-release tablet subject idiopathic Parkinson 's disease currently treat stable regimen carbidopa-levodopa immediate-release tablet .</brief_summary>
	<brief_title>Pharmacokinetics Pharmacodynamics IPX054 Subjects With Parkinson 's Disease</brief_title>
	<detailed_description>IPX054 contain two different drug call levodopa carbidopa one tablet . - levodopa turn material call 'dopamine ' brain . The dopamine help improve symptom Parkinson 's disease . - carbidopa belongs group medicine call 'aromatic amino acid decarboxylase inhibitor ' . It help levodopa work effectively slow speed levodopa break body .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<criteria>Clinical diagnosis idiopathic Parkinson 's disease Currently treat stable dosage regimen immediaterelease carbidopalevodopa least 3 month . Must experience least 3 episode `` wear OFF '' symptom average least 2 hour `` OFF '' time per day . Diagnosed atypical parkinsonism Prior surgical intervention Parkinson 's disease Glaucoma Undiagnosed skin lesion history melanoma Epilepsy history seizure</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>IPX054</keyword>
	<keyword>Parkinson disease</keyword>
	<keyword>Levodopa</keyword>
</DOC>